A full 79 % of heart attack patients left hospitals with prescriptions for the recommended medication. Aspirin. Fighting, beta blockers, ACE inhibitors and statins for high cholesterol but raised when this number was 85 %, 250 saved saved each year, suggested the study.
– Kathryn W. Woodburn, Senior Director, Preclinical Development at Affymax presented an abstract antibody-mediated pure red cell aplasia with a peptidic erythropoiesis stimulating agent in the rat, ‘during an oral session. This preclinical study evaluated the effect of a Hematide-related peptide in a model of pure red cell aplasia , when patients mount a neutralizing antibody response to recombinant human erythropoietin therapy developed. The study results showed that , the Hematide-related peptide hemoglobin and correct anemia, the increase EPO – EPO – specific antibodies in animal models.. Affymax presented preclinical data on a Hematide -related peptide at the American Society of Nephrology Renal Week 2006Affymax, is a pharmaceutical company engaged in the clinical phase, today announced the presentation of preclinical data on a Hematide – related peptide at the American Society of Nephrology Renal Week 2006 in San Diego.For further information about NIH and its programs.. The National Institutes of Health – The Country Medical Research Agency – comprises 27 Institutes and Centers and is part of U.S. Department of Health and Human Services. It is the primary federal authority to implement and promotion of basic research, clinical and translational medical science, and it examines the causes, treatments, and cures for both common and rare illnesses.